Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Türeci, Ӧzlem"'
Autor:
Haranaka, Miwa, Baber, James, Ogama, Yoichiro, Yamaji, Masako, Aizawa, Masakazu, Kogawara, Osamu, Scully, Ingrid, Lagkadinou, Eleni, Türeci, Ӧzlem, Şahin, Uğur, Dormitzer, Philip R., Gruber, William C., Lockhart, Stephen
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Nature Communications
Nature Communications
We report interim safety and immunogenicity findings from an ongoing phase 1/2 study of BNT162b2 in healthy Japanese adults. Participants were randomized 3:1 to receive 2 intramuscular injections of 30 μg BNT162b2 or placebo 21 days apart. Overall,
Autor:
Simões, Eric A F, Klein, Nicola P, Sabharwal, Charu, Gurtman, Alejandra, Kitchin, Nicholas, Ukkonen, Benita, Korbal, Piotr, Zou, Jing, Xie, Xuping, Sarwar, Uzma N, Xu, Xia, Lockhart, Stephen, Cunliffe, Luke, Lu, Claire, Ma, Hua, Swanson, Kena A, Koury, Kenneth, Shi, Pei-Yong, Cooper, David, Türeci, Ӧzlem
Publikováno v:
Journal of the Pediatric Infectious Diseases Society; Apr2023, Vol. 12 Issue 4, p234-238, 5p
Autor:
Fergie, Jaime, Moran, Mary M., Cane, Alejandro, Pather, Shanti, Türeci, Ӧzlem, Srivastava, Amit
Publikováno v:
Vaccines; Dec2022, Vol. 10 Issue 12, p2039, 18p
Publikováno v:
OncoImmunology; 2019, Vol. 8 Issue 1, p1-1, 1p
Autor:
Türeci Ӧ; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Mitnacht-Kraus R; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Wöll S; Formerly of Ganymed Pharmaceuticals AG, Mainz, Germany., Yamada T; Astellas Pharma, Inc., Tokyo, Japan., Sahin U; TRON - Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2018 Nov 10; Vol. 8 (1), pp. e1523096. Date of Electronic Publication: 2018 Nov 10 (Print Publication: 2019).